527 related articles for article (PubMed ID: 11697899)
1. Biological significance of a small highly conserved region in the N terminus of the p53 tumour suppressor protein.
Liu WL; Midgley C; Stephen C; Saville M; Lane DP
J Mol Biol; 2001 Nov; 313(4):711-31. PubMed ID: 11697899
[TBL] [Abstract][Full Text] [Related]
2. The conformationally flexible S9-S10 linker region in the core domain of p53 contains a novel MDM2 binding site whose mutation increases ubiquitination of p53 in vivo.
Shimizu H; Burch LR; Smith AJ; Dornan D; Wallace M; Ball KL; Hupp TR
J Biol Chem; 2002 Aug; 277(32):28446-58. PubMed ID: 11925449
[TBL] [Abstract][Full Text] [Related]
3. MdmX protects p53 from Mdm2-mediated degradation.
Jackson MW; Berberich SJ
Mol Cell Biol; 2000 Feb; 20(3):1001-7. PubMed ID: 10629057
[TBL] [Abstract][Full Text] [Related]
4. Multiple lysine mutations in the C-terminus of p53 make it resistant to degradation mediated by MDM2 but not by human papillomavirus E6 and induce growth inhibition in MDM2-overexpressing cells.
Nakamura S; Roth JA; Mukhopadhyay T
Oncogene; 2002 Apr; 21(16):2605-10. PubMed ID: 11971195
[TBL] [Abstract][Full Text] [Related]
5. Multiple lysine mutations in the C-terminal domain of p53 interfere with MDM2-dependent protein degradation and ubiquitination.
Nakamura S; Roth JA; Mukhopadhyay T
Mol Cell Biol; 2000 Dec; 20(24):9391-8. PubMed ID: 11094089
[TBL] [Abstract][Full Text] [Related]
6. N-terminal 130 amino acids of MDM2 are sufficient to inhibit p53-mediated transcriptional activation.
Leng P; Brown DR; Shivakumar CV; Deb S; Deb SP
Oncogene; 1995 Apr; 10(7):1275-82. PubMed ID: 7731677
[TBL] [Abstract][Full Text] [Related]
7. p53 Stability and activity is regulated by Mdm2-mediated induction of alternative p53 translation products.
Yin Y; Stephen CW; Luciani MG; FĂ„hraeus R
Nat Cell Biol; 2002 Jun; 4(6):462-7. PubMed ID: 12032546
[TBL] [Abstract][Full Text] [Related]
8. An N-terminal p14ARF peptide blocks Mdm2-dependent ubiquitination in vitro and can activate p53 in vivo.
Midgley CA; Desterro JM; Saville MK; Howard S; Sparks A; Hay RT; Lane DP
Oncogene; 2000 May; 19(19):2312-23. PubMed ID: 10822382
[TBL] [Abstract][Full Text] [Related]
9. p53 mutants can often transactivate promoters containing a p21 but not Bax or PIG3 responsive elements.
Campomenosi P; Monti P; Aprile A; Abbondandolo A; Frebourg T; Gold B; Crook T; Inga A; Resnick MA; Iggo R; Fronza G
Oncogene; 2001 Jun; 20(27):3573-9. PubMed ID: 11429705
[TBL] [Abstract][Full Text] [Related]
10. Binding to the naturally occurring double p53 binding site of the Mdm2 promoter alleviates the requirement for p53 C-terminal activation.
Kaku S; Iwahashi Y; Kuraishi A; Albor A; Yamagishi T; Nakaike S; Kulesz-Martin M
Nucleic Acids Res; 2001 May; 29(9):1989-93. PubMed ID: 11328884
[TBL] [Abstract][Full Text] [Related]
11. The N terminus of the murine p53 tumour suppressor is an independent regulatory domain affecting activation and thermostability.
Hansen S; Lane DP; Midgley CA
J Mol Biol; 1998 Jan; 275(4):575-88. PubMed ID: 9466932
[TBL] [Abstract][Full Text] [Related]
12. Over-expression of the human MDM2 p53 binding domain by fusion to a p53 transactivation peptide.
Liu Z; Olejniczak ET; Fesik SW
Protein Expr Purif; 2004 Oct; 37(2):493-8. PubMed ID: 15358376
[TBL] [Abstract][Full Text] [Related]
13. Analysis of the degradation function of Mdm2.
Kubbutat MH; Ludwig RL; Levine AJ; Vousden KH
Cell Growth Differ; 1999 Feb; 10(2):87-92. PubMed ID: 10074902
[TBL] [Abstract][Full Text] [Related]
14. The contribution of the RING finger domain of MDM2 to cell cycle progression.
Argentini M; Barboule N; Wasylyk B
Oncogene; 2000 Aug; 19(34):3849-57. PubMed ID: 10951578
[TBL] [Abstract][Full Text] [Related]
15. The corepressor mSin3a interacts with the proline-rich domain of p53 and protects p53 from proteasome-mediated degradation.
Zilfou JT; Hoffman WH; Sank M; George DL; Murphy M
Mol Cell Biol; 2001 Jun; 21(12):3974-85. PubMed ID: 11359905
[TBL] [Abstract][Full Text] [Related]
16. A mouse p53 mutant lacking the proline-rich domain rescues Mdm4 deficiency and provides insight into the Mdm2-Mdm4-p53 regulatory network.
Toledo F; Krummel KA; Lee CJ; Liu CW; Rodewald LW; Tang M; Wahl GM
Cancer Cell; 2006 Apr; 9(4):273-85. PubMed ID: 16616333
[TBL] [Abstract][Full Text] [Related]
17. A genetic approach to mapping the p53 binding site in the MDM2 protein.
Freedman DA; Epstein CB; Roth JC; Levine AJ
Mol Med; 1997 Apr; 3(4):248-59. PubMed ID: 9131587
[TBL] [Abstract][Full Text] [Related]
18. Association of p19(ARF) with Mdm2 inhibits ubiquitin ligase activity of Mdm2 for tumor suppressor p53.
Honda R; Yasuda H
EMBO J; 1999 Jan; 18(1):22-7. PubMed ID: 9878046
[TBL] [Abstract][Full Text] [Related]
19. Critical role for Ser20 of human p53 in the negative regulation of p53 by Mdm2.
Unger T; Juven-Gershon T; Moallem E; Berger M; Vogt Sionov R; Lozano G; Oren M; Haupt Y
EMBO J; 1999 Apr; 18(7):1805-14. PubMed ID: 10202144
[TBL] [Abstract][Full Text] [Related]
20. Mdm2 binding to a conformationally sensitive domain on p53 can be modulated by RNA.
Burch LR; Midgley CA; Currie RA; Lane DP; Hupp TR
FEBS Lett; 2000 Apr; 472(1):93-8. PubMed ID: 10781812
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]